nach oben

BMC Cardiovascular Disorders

Erschienen in:

Open Access 01.12.2019 | Research article

Prognostic significance of factor XIIIA promoter methylation status in aneurysmal subarachnoid haemorrhage (aSAH)

verfasst von: S. Arati, G. K. Chetan, M. K. Sibin, Dhananjaya I. Bhat, Vikas Vazhayil, K. V. L. Narasingarao

Erschienen in: BMC Cardiovascular Disorders | Ausgabe 1/2019

Abstract

Background

Aneurysmal subarachnoid hemorrhage is a life- threatening condition with high rate of disability and mortality. Apolipoprotein E (APOE) and Factor XIIIA (F13A) genes are involved in the pathogenetic mechanism of aneurysmal subarachnoid haemorrhage (aSAH).

We evaluated the association of promoter methylation status of APOE and F13A gene and risk of aSAH.

Methods

For evaluating the effect of hypermethylation in the promoter region of these genes with risk of aSAH, we conducted a case -control study with 50 aSAH patients and 50 healthy control. The methylation pattern was analysed using methylation specific PCR. The risk factors associated with poor outcome after aSAH was also analysed in this study. The outcome was assessed using Glasgow outcome score (GOS) after 3 months from the initial bleed.

Results

The frequency of APOE and F13A methylation pattern showed insignificant association with risk of aSAH in this study. Gender stratification analysis suggests that F13A promoter methylation status was significantly associated with the risk of aSAH in male gender. Age, aneurysm located at the anterior communicating artery and diabetes mellitus showed significant association with poor outcome after aSAH.

Conclusion

There was no significant association with APOE promoter methylation with the risk as well as outcome of patients after aSAH. F13A promoter methylation status was significantly associated with risk of aSAH in male gender, with no significant association with outcome after aSAH.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

ACOM

Anterior communicating artery

aSAH

Aneurysmal subarachnoid haemorrhage;

Confidence interval

F13A

Factor XIII a subunit

ICA

Internal carotid artery

MCA

Middle cerebral artery

Odds ratio

PCOM

Posterior communicating artery

WFNS

World Federation of Neurological Surgeons

Background

Aneurysmal subarachnoid hemorrhage (aSAH) is a worldwide disease condition which causes permanent disability and high rate of mortality [1]. The worldwide incidence rate of SAH is about 9/ 100,000 persons/year with regional differences. Most important risk factors for the rupture of aneurysm were female gender, hypertension, size and location of aneurysm [2]. Epigenetic mechanisms such as DNA methylation, histone modification and RNA Interference were associated with aging mechanisms and cause risk for cardiovascular and hemorrhagic stroke [3]. In DNA methylation, the cytosine at the CpG islands in the promoter region is methylated at the 5′ carbon position by DNA methyltransferase (DNMT). DNA methylation is associated with long term gene silencing without altering nucleotide sequence of the DNA [4]. The prognosis of SAH depends on the amount of initial bleed, re-bleeding, chance of delayed cerebral ischemia, stress hyperglycemia, and elevated d-dimer levels [5].

In CNS, Apolipoprotein E (APOE) protein is synthesized by astrocytes. The main function is to transport cholesterol and triglycerides. APOE is involved in pathogenic mechanism of aneurysm formation by regulating inflammatory responses [6] and triggering atherosclerosis [7]. APOE gene is in the chromosome 19q13.The gene consists of four exons and three introns which gives mRNA of 1163 nucleotides [8]. The promoter region of APOE gene spanning from − 1017 to + 406 has three major SNP [9] and contributed to a major risk factor for Alzheimer’s disease in Italian case -control study [10]. There was a functional difference between APOE 3′ and 5′ CpG islands. The 3’CpG islands were methylated in all tissues expect sperm and was not repressed whereas the 5’CpG islands methylation led to transcriptional repression [11]. The GC content of APOE promoter region was about 58%, a minimum content of 42% and a maximum of 82% [12].

Factor XIIIA (F13A), also called as fibrin stabilizing factor, is an important enzyme in the blood coagulation system [13]. The main function of F13A is to cross link fibrin to form the final blood clot [14]. The F13A gene is located in the chromosome 6p25.1 [15]. The hyper methylation of F13A promoter region repress the gene transcription and the deficiency of F13A causes life threatening central nervous system bleeding [16]. Fibrinolytic system dysfunction is another pathogenic mechanism that contributes to aSAH [17, 18]. F13A is an important enzyme in the fibrinolytic system. It was reported that fibrinolytic system interacts with components of extra cellular matrix remodelling and contributes to the risk of haemorrhage [19, 20].

There are many studies which describes the association of APOE and F13A polymorphism and the risk of aSAH. But studies which explains the role of epigenetic mechanisms in APOE and F13A genes with the risk of aSAH are very less. In the present study, we have analysed the association of promoter methylation status of APOE and F13A gene with the risk of aSAH and its association with the outcome of patients after aSAH.

Methods

Study population

The blood samples of 50 aSAH patients and 50 age and sex matching healthy controls were included in the study. The characteristics of study population were already published previously (DOI: https://doi.org/10.1186/s12881-018-0674-x). The WFNS scale is widely used to classify patients based on Glasgow coma scale (GCS). WFNS grade II has GCS of 14 in the absence of motor deficit whereas WFNS grade III has GCS of 13 with the presence of motor deficit. Outcome was assessed using Glasgow outcome score (GOS) after 3 months from the initial bleed. Poor outcome was defined according to GOS as severe or worse disability.

DNA isolation, bisulfite modification, methylation specific PCR (MS-PCR)

Two millilitre blood was taken from all the participants and DNA was isolated from each blood sample using the commercially available Machery-Nagel (MN) kit according to manufacturer’s protocol. Purity and quantity of DNA was analysed by Nanodrop ND2000c spectrophotometer. DNA with a purity of 1.75–1.85 was used for Bisulfite modification. 2 μg of DNA was isolated from blood and was bisulfite modified using EpiTech Bisulfite Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol. 200 bp and 100 bp fragment of APOE and F13A promoter was amplified by MS PCR from bisulfite treated DNA using methylated and unmethylated primers. Methyl primer express software, version 1.0 (Applied Biosystems) was used to design the methylated and unmethylated primers for APOE and F13A promoters as shown in Table 1. The reaction for MS -PCR was prepared for a final volume of 10 μl, which contain 5 μl PCR master mix (EmeraldAmp GT 2X), 2 μl primer (2 μm),2 μl DNA (2 μg),1 μl distilled water. The MS -PCR conditions were initial incubation at 95⁰ C for 10 min followed by 40 cycles of denaturation at 95 °C for 30 s, annealing at 56 °C (APOE methylated and unmethylated primers) for 22 s, annealing at 58 °C (F 13A methylated and unmethylated primers) for 32 s and extension at 72 °C for 30 s. The PCR products were electrophoresed on 2% agarose gel which was stained with ethidium bromide and was visualized under gel documentation system (Biorad, GelDoc EZ imager).

Table 1

Primer Sequences and Annealing Temperatures

Gene	Sequence (5′-3′)	Annealing temperature	Product size
APOE M	5′ GTTGGGGTTAGTTGATGTTTATTAC 3′ (FORWARD) 5′ AAAAAAACTAAACTCCTAATTCGAA 3′ (REVERSE)	56 °C	200 bp
APOE UM	5′ GGTTGGGGTTAGTTGATGTTTATTAT 3′ (FORWARD) 5′ AAAAAAACTAAACTCCTAATTCAAA 3′ (REVERSE)	56 °C	200 bp
FXIII M	5′ AGAAGCGAGGGTTTTTGTTC 3′ (FORWARD) 5′ AACAATATAACGCGCTATCG 3′ (REVERSE)	58 °C	100 bp
FXIII UM	5′ TAGAAGTGAGGGTTTTTGTTT 3′ (FORWARD) 5′ AACAATATAACACACTATCAAAA 3′ (REVERSE)	58 °C	100 bp

Statistical analysis

The continuous variable was expressed as mean ± SD. The normal distribution of data was checked using Shapiro-Wilk test. Categorical data were tested using Pearson’s χ². The odds ratio with 95% confidence interval (CI) was estimated to assess the methylation status and risk of aSAH. The interaction of various risk factors and poor outcome at 3 months after aSAH was analysed with logistic regression analysis for estimating the univariate and multivariate odds ratio and 95% CI. All statistical analysis was done using R.3.0.11 statistical software. The P value < 0.05 was considered as statistically significant.

Results

There was no significant difference in age, gender, hypertension and diabetes mellitus between aSAH patients and control. The demographic characteristics of patients and controls are shown in Table 2. The methylation frequency for APOE gene was 64% for aSAH patients and 60% for controls. There was no statistically significant difference in methylation and unmethylation pattern in the promoter region of APOE gene between cases and control (p = 0.836). The promoter methylation analysis of APOE gene in aSAH patients and controls are shown in Table 3. Figure 1 represents the methylation status of APOE promoter region by MS -PCR of aSAH patients and healthy controls.

Table 2

Demographic characteristics of aSAH patients and healthy controls

Variables	Patients(50)	Control(50)	P Value
Age	51.58 ± 10.41	56.64 ± 13.67	0.07
Gender (Male/Female)	19/31	20/30	0.83
Hypertension (Yes/No)	28/22	34/16	0.21
Diabetes mellitus (Yes/No)	27/23	21/29	0.23
Alcohol consumption (Yes/No)	15/35	20/30	0.29
Smoking (Yes/No)	11/39	18/32	0.12
Site of aneurysm (%)
ACOM*	23	/
PCOM*	4	/
ICA*	9	/
MCA*	5	/
Multiple	9	/
Size of aneurysm (%)
Small(< 15 mm)	38	/
Large(15-25 mm)	10	/
Giant(> 25 mm)	2	/
WFNS Grade (%)
Grade II	25	/
Grade III	25	/

^*ACOM anterior communicating artery, PCOM posterior communicating artery, MCA middle cerebral artery, ICA internal carotid artery

Table 3

Promoter Methylation Analysis of APOE and Factor XIII gene in aSAH patients and healthy controls

Characteristics	Methylated (%)	Unmethylated (%)	p- value
APOE
All
Cases(n = 50)	32 (64)	18 (36)	0.836
Control (n = 50)	30 (60)	20 (40)	0.836
Females
Cases(n = 31)	19	12	0.90
Control(n = 30)	18	12	0.90
Males
Cases (n = 19)	13	6	0.830
Controls (n = 20)	12	8	0.830
F13A
All
Cases (n = 50)	37 (74)	13 (26)	0.283
Control (n = 50)	31 (62)	19 (38)	0.283
Females
Cases(n = 31)	23	8	0.90
Control(n = 30)	23	7	0.90
Males
Cases (n = 19)	14	5	0.07
Controls (n = 20)	8	12	0.07

Likewise, the methylation frequency of F13A gene was 74% for aSAH patients and 62% for controls. The promoter methylation and unmethylation pattern of F13A gene between cases and control had no statistically significant difference (p = 0.283). The promoter methylation analysis of F13A gene in aSAH patients and controls are shown in Table 3. Figure 2 represents the analysis of methylation status of F13A promoter region by MS -PCR of aSAH patients and healthy controls.

The promoter methylation and unmethylation status of APOE (OR = 1.35;95%CI = .58–3.16; p = 0.483) and F13A (OR = 1.37;95%CI = 0.53–.3.53;p = 0.511) genes were not significantly associated with the risk of aSAH after adjustment for covariates as shown in Table 4. Gender stratification analysis showed that F13A promoter methylation status was significantly associated with risk of aSAH in male gender (OR = 4.2;95% CI = 1.08–16.32;p = 0.03).

Table 4

Risk of aSAH based on gene promoter methylation status

Genes	Methylation Status	Crude OR (95% CI)	p-value	Adjusted OR^a (95%CI)	p-value
APOE	U (reference)	1.19 (0.52–2.66)	0.680	1.35 (0.58–3.16)	0.483
APOE	M	1.19 (0.52–2.66)	0.680	1.35 (0.58–3.16)	0.483
F13A	U (reference)	1.74 (0.74–4.09)	0.200	1.37 (0.53–3.53)	0.511
F13A	M	1.74 (0.74–4.09)	0.200	1.37 (0.53–3.53)	0.511

OR odds ratio, U unmethylation, M methylation

^aAdjusted for smoking, alcohol consumption, hypertension and diabetes

Univariate and multivariate risk factors for poor outcomes are shown in Table 5. Both univariate and multivariate analysis showed that patients with aneurysm located at anterior communicating artery (ACOM) (OR = 0.15,95%CI =0.04–0.52,P = 0.0028) and diabetes mellites (OR = 3.75, 95%CI = 1.16–12.1,P = 0.03) have association with poor outcome independent of other factors. Also, our study showed age ≥ 50 years can be one of the risk factors for poor outcome in both multivariate and univariate analysis. Of the subjects with APOE promoter methylation status (n = 32), 50% had good outcome and 50% had poor outcome. Likewise, the F13A promoter methylation subjects (n = 37), 54% had good outcome and 45% had poor outcome. The promoter methylation status of APOE and F13A were not associated with outcome either in univariate or multivariate analysis.

Table 5

Risk factors for poor outcome after aSAH

Characteristics	Univariate OR(95%CI)	p	Multivariate OR(95%CI)	p
Age (≥50& ≤ 50)	6.08 (1.71–21.49)	0.0051	5.29 (1.02–27.50)	0.047
WFNS grade (2&3)	1.00 (0.33–3.03)	1.00	–	–
Location
ACOM*	0.15 (0.04–0.52)	0.0028	0.06 (0.009–0.38)	0.003
PCOM*	3.00 (0.29–31.00)	0.35	–
MCA*	4.18 (0.43–40.40)	0.216	–
ICA*	2.58 (0.58–11.40)	0.21	–
MULTIPLE	2.10 (0.46–9.56)	0.337	–
Size
Small	1.73 (0.46–6.43)	0.41	2.30 (0.35–15.00)	0.38
Large	0.54 (0.13–2.23)	0.40	–	–
Giant	0.92 (0.05–15.60)	0.95	–	–
Sex	1.04 (0.33–3.27)	0.94	–	–
Hypertension	0.60 (0.19–1.85)	0.38	–	–
Diabetes mellites	3.75 (1.16–12.1)	0.03	6.20 (1.01–38.00)	0.04
Smoking	0.44 (0.11–1.76)	0.25	–	–
Alcohol Consumption	0.50 (0.14–1.71)	0.27	–	–
Methylation
APOE	0.80 (0.25–2.55)	0.70	0.72 (0.14–3.56)	0.68
Methylation
FACTOR XIII	1.37 (0.38–4.88)	0.62	1.76 (0.30–10.10)	0.53

*ACOM anterior communicating artery; PCOM posterior communicating artery; MCA middle cerebral artery; ICA internal carotid artery

Discussion

Aneurysmal subarachnoid haemorrhage is a complex disease condition in which both genetic and environmental factors play a key role. Aneurysmal re-bleeding and delayed cerebral ischemia (DCI) are two major complications following aSAH that have increased mortality and poor prognosis [21]. Poor outcome is mainly characterised by the degree of initial bleed, size of aneurysm and age of patients at disease onset, high blood pressure, and hyperglycemia [5]. The first-degree relatives of patients with aSAH are 3 to5fold risker of having this disease than the general population [22]. However, not much information is available on the genes involved. Epigenetics modification can occur throughout the development and differentiation and in response to environmental stimuli [23]. DNA methylation is an epigenetic modification that is important for the regulation of gene expression.

Atherosclerosis is one of the pathogenetic mechanism for the formation of aneurysm [6]. Disturbed balance of lipid accumulation is one of the reasons for atherosclerosis [24]. Hypermethylation in the promoter region of various gene has been identified with the association of atherosclerosis progression [25]. APOE gene expression have been widely investigated in multiple disease condition. The APOE gene plays a key role in lipid metabolism by binding to cell surface lipoprotein receptors [26]. The APOE gene promoter methylation can alter the gene regulation and function. In our study we found that 64% of patient population and 60% of control population has methylation on APOE promoter region. Similarly, study done by Kordi-Tamandani et al. on the association of APOE promoter methylation with Schizophrenia in Asian population showed 80% of control population has methylated promoter region [27]. There is a significant difference in the APOE promoter methylation status with the present study (χ2 = 8.87; p value = 0.003). None of the above studies showed any significant association of APOE promoter methylation with these diseases. In-vitro study showed that APOE promoter polymorphism (− 219 G/T) modifies APOE expression in vitro and influences the binding to the estrogen receptor [28]. There are studies which highlights the association of APOE isoforms (ε2,ε3,ε4) in the exon 4 region with the risk of aSAH [29‐31].

Factor XIII A (F13A) is a transglutaminase enzyme that circulates in the plasma and has two catalytic A subunit and two carrier B subunit [32]. Study done by Lu et al. suggests that demethylation of promoter in vivo increases the transglutaminase activity and hypermethylation of the transglutaminase promoter in vitro suppressed its activity [33]. Human transglutaminase gene expression can be regulated by methylation. In-vitro study showed that human transglutaminase promoter has three CpG rich domains of which two were fully methylated [34]. The difference between F13A subunit and transglutaminase gene is, F13A subunit gene has exon 1 encoding at 5’untranslated region and exon 2 has translational start site where as transglutaminase has translational start site at exon 1 [35].

In our study 74% of patients had methylated F13A promoter. The transcriptional repression of F13A gene leads to fibrinolytic dysfunction like increased bleeding [36]. In platelets and monocytes, F13A is present as cellular Factor XIIIA (cFXIII) [32]. Cellular FXIII has a key role in the progression of atherosclerosis by activating monocytes and helps adhesion of monocytes to endothelium [37]. Genetic variants at a specific locus can influence both regional and distant DNA methylation. Val34Leu polymorphism in F13A gene present on exon 2 of A subunit showed association with the risk of aSAH in many population [18, 20, 38]. Val34Leu polymorphism increases the activation rate and affects the fibrin structure [39]. Genetic variation in F13A gene encoding epigenetic factors can modify the risk of neurological disease onset and progression. The genetic risk and functional outcome after aSAH can be monitored with the SNP analysis and DNA methylation studies.

The present study had a greater number of cases with methylated F13A promoter region. Smoking level was seen higher in the control samples when compared to cases. Smoking is considered as the most powerful environmental modifier of DNA methylation. DNA methylation is significantly lower in smokers than non-smokers. There is a positive correlation between smoking level and F13A levels. The negative correlation between DNA methylation and F13A levels may explain the reason for lower methylation levels in control samples.

aSAH outcome were assessed using GOS at a similar time point (3 months) after aSAH in all the participants. Participants were recruited from all the eligible patients from the study hospital with recent aSAH. Recruitment of participants were done with a reduced risk of selection bias and a range of independent variables were included in the study with reasonable follow up rate. APOE and F13A promoter methylation was not associated with poor outcome in our study. But in our study, age, diabetes mellitus and ACOM aneurysm were independently associated with poor outcome in post aSAH cohort.

There are reasons to suggest the methylated genes as a good prognostic marker. Some of these reasons include the following: (a) DNA is a stable molecule which can be easily extracted from body fluids and tissues (b) detection of methylation percentage can be considered as an important marker to check gene expression change (c) Methylation tests might have clinical importance since they are non-invasive [40]. Epigenetic biomarkers can be easily extracted from body liquids such as blood, saliva, or urine and used to identify and diagnose neurological disorders at the initial phase of disease [41]. Methylation at specific loci in DNA from peripheral blood leukocytes/whole blood was first reported in lung cancer [42]. In epigenetic epidemiology, DNA from peripheral blood can be used for methylation analysis when target tissue for diseases such as aSAH was not readily available [43]. Study done by Ma et al., (2015) suggests that there was no significant variability in APOE promoter methylation levels between brain and blood tissue [44]. Large prospective studies are required to understand whether F13A DNA methylation patterns in WBC represent F13A expression levels on the pathogenic pathways that links to disease end points.

Conclusion

In conclusion, epigenetics is at an early stage, but it is a promising area of analysis in aSAH treatment and recovery. Our study enacts a crucial step to clarify the role of APOE and F13A promoter methylation status with risk of aSAH in a South Indian population. In future, the information about the relationship between epigenetic variations and the risk of aSAH as well as its complications can help in the discovery of new treatment and therapies.

Acknowledgements

Arati S acknowledges Department of Science and Technology (DST) [SR/WOS A/LS-1040/2014], Government of India for providing Women Scientist fellowship.

The study protocol was approved by the Institute of Ethics Committee for Human Studies, NIMHANS, Bangalore, India (Item No. III, Sl.No.3.02, Basic Sciences). Written informed consent was obtained from all the participants.

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

D’Souza S. Aneurysmal subarachnoid hemorrhage. J Neurosurg Anesthesiol. 2015;27(3):222.PubMedPubMedCentralCrossRef

Wermer MJ, Van der Schaaf IC, Algra A, Rinkel GJ. Risk of rupture of unruptured intracranial aneurysms in relation to patient and aneurysm characteristics. Stroke. 2007;38(4):1404–10.PubMedCrossRef

Soriano-Tárraga C, Jiménez-Conde J, Giralt-Steinhauer E, Mola M, Ois Á, Rodríguez-Campello A, Cuadrado-Godia E, Fernández-Cadenas I, Carrera C, Montaner J, Elosua R. Global DNA methylation of ischemic stroke subtypes. PLoS One. 2014;9(4):96543.CrossRef

Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38(1):23.PubMedCrossRef

Juvela S, Siironen J, Lappalainen J. Apolipoprotein E genotype and outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2009;110(5):989–95.PubMedCrossRef

Chalouhi N, Ali MS, Jabbour PM, Tjoumakaris SI, Gonzalez LF, Rosenwasser RH, Koch WJ, Dumont AS. Biology of intracranial aneurysms: role of inflammation. J Cereb Blood Flow Metab. 2012;32(9):1659–76.PubMedPubMedCentralCrossRef

Grimaldi V, Vietri MT, Schiano C, Picascia A, De Pascale MR, Fiorito C, Casamassimi A, Napoli C. Epigenetic reprogramming in atherosclerosis. Curr Atheroscler Rep. 2015;17(2):476.PubMedCrossRef

Paik YK, Chang DJ, Reardon CA, Davies GE, Mahley RW, Taylor JM. Nucleotide sequence and structure of the human apolipoprotein E gene. Proc Natl Acad Sci. 1985;82(10):3445–9.PubMedCrossRef

Wu HT, Ruan J, Zhang XD, Xia HJ, Jiang Y, Sun XC. Association of promoter polymorphism of apolipoprotein E gene with cerebral vasospasm after spontaneous SAH. Brain Res. 2010;1362:112–6.PubMedCrossRef

10.

Bizzarro A, Seripa D, Acciarri A, Matera MG, Pilotto A, Tiziano FD, Brahe C, Masullo C. The complex interaction between APOE promoter and AD: an Italian case–control study. Eur J Hum Genet. 2009;17(7):938.PubMedPubMedCentralCrossRef

11.

Larsen F, Solheim J, Prydz H. A methylated CpG island 3'in the apolipoprotein-E gene does not repress its transcription. Hum Mol Genet. 1993;2(6):775–80.PubMedCrossRef

12.

Maloney B, Ge YW, Alley GM, Lahiri DK. Important differences between human and mouse APOE gene promoters: limitation of mouse APOE model in studying Alzheimer’s disease. J Neurochem. 2007;103(3):1237–57.PubMedCrossRef

13.

Shi DY, Wang SJ. Advances of Coagulation Factor XIII. Chinese Med J. 2017;130(2):219.

14.

Aleman MM, Byrnes JR, Wang JG, Tran R, Lam WA, Di Paola J, Mackman N, Degen JL, Flick MJ, Wolberg AS. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest. 2014;124:3590.PubMedPubMedCentralCrossRef

15.

Ichinose A, Davie EW. Characterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor. Proc Natl Acad Sci. 1988;85:5829–33.PubMedCrossRef

16.

Dorgalaleh A, Alizadeh S, Tabibian S, Taregh B, Karimi M. The PAI-I Gene 4G/5G polymorphism and central nervous system bleeding in factor XIII deficiency. Blood. 2013;4782.

17.

Colaianni V, Mazzei R, Cavallaro S. Copy number variations and stroke. Neurol Sci. 2016;37:1895–904.PubMedPubMedCentralCrossRef

18.

Reiner AP, Schwartz SM, Frank MB, Longstreth WT, Hindorff LA, Teramura G, Rosendaal FR, Gaur LK, Psaty BM, Siscovick DS. Polymorphisms of coagulation factor XIII subunit a and risk of nonfatal hemorrhagic stroke in young white women. Stroke. 2001;32(11):2580–7.PubMedCrossRef

19.

Yang Z, Eton D, Zheng F, Livingstone AS, Yu H. Effect of tissue plasminogen activator on vascular smooth muscle cells. J Vasc Surg. 2005;42(3):532–8.PubMedCrossRef

20.

Ladenvall C, Csajbok L, Nylén K, Jood K, Nellgård B, Jern C. Association between factor XIII single nucleotide polymorphisms and aneurysmal subarachnoid hemorrhage. J Neurosurg. 2009;110(3):475–81.PubMedCrossRef

21.

Rosengart AJ, Schultheiss KE, Tolentino J, Macdonald RL. Prognostic factors for outcome in patients with aneurysmal subarachnoid hemorrhage. Stroke. 2007;38(8):2315–21.PubMedCrossRef

22.

Lonjon M, Pennes F, Sedat J, Bataille B. Epidemiology, genetic, natural history and clinical presentation of giant cerebral aneurysms. Neurochirurgie. 2015;61(6):361–5.PubMedCrossRef

23.

Kim S, Kaang BK. Epigenetic regulation and chromatin remodeling in learning and memory. Exp Mol Med. 2017;49(1):281.CrossRef

24.

Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008;54(1):24–38.PubMedCrossRef

25.

Byrne MM, Murphy RT, Ryan AW. Epigenetic modulation in the treatment of atherosclerotic disease. Front Genet. 2014;5:364.PubMedPubMedCentralCrossRef

26.

Huang Y, Mahley RW. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. Neurobiol Dis. 2014;72:3–12.PubMedCrossRef

27.

Kordi-Tamandani DM, Najafi M, Mojahad A. Apoe and cpt1-a promoter methylation and expression profiles in patients with schizophrenia. Gene Cell Tissue. 2014;1:1.CrossRef

28.

Lambert JC, Coyle N, Lendon C. The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer’s disease. J Med Genet. 2004;41(2):104–12.PubMedPubMedCentralCrossRef

29.

Liu H, Mao P, Xie C, Xie W, Wang M, Jiang H. Apolipoprotein E polymorphism and the risk of intracranial aneurysms in a Chinese population. BMC Neurol. 2016;16(1):14.PubMedPubMedCentralCrossRef

30.

Tang J, Zhao J, Zhao Y, Wang S, Chen B, Zeng W. Apolipoprotein e ϵ4 and the risk of unfavorable outcome after aneurysmal subarachnoid hemorrhage. Surg Neurol. 2003;60:391–6.PubMedCrossRef

31.

Kaushal R, Woo D, Pal P, Haverbusch M, Xi H, Moomaw C, Sekar P, Kissela B, Kleindorfer D, Flaherty M, Sauerbeck L. Subarachnoid hemorrhage: tests of association with apolipoprotein E and elastin genes. BMC Med Genet. 2007;8:49.PubMedPubMedCentralCrossRef

32.

Schröder V, Kohler HP. New developments in the area of factor XIII. J Thromb Haemost. 2013;11(2):234–44.CrossRef

33.

Lu S, Davies PJ. Regulation of the expression of the tissue transglutaminase gene by DNA methylation. Proc Natl Acad Sci. 1997;94(9):4692–7.PubMedCrossRef

34.

Cacciamani T, Virgili S, Centurelli M, Bertoli E, Eremenko T, Volpe P. Specific methylation of the CpG-rich domains in the promoter of the human tissue transglutaminase gene. Gene. 2002;297:103–12.PubMedCrossRef

35.

Kida M, Souri M, Yamamoto M, Saito H, Ichinose A. Transcriptional regulation of cell type-specific expression of the TATA-less a subunit gene for human coagulation factor XIII. J Biol Chem. 1999;274(10):6138–47.PubMedCrossRef

36.

Dorgalaleh A, Rashidpanah J. Blood coagulation factor XIII and factor XIII deficiency. Blood Rev. 2016;30:461–75.PubMedCrossRef

37.

Richardson VR, Cordell P, Standeven KF, Carter AM. Substrates of factor XIII-A: roles in thrombosis and wound healing. Clin Sci. 2013;124(3):123–37.PubMedCrossRef

38.

Ruigrok YM, Slooter AJ, Rinkel GJ, Wijmenga C, Rosendaal FR. Genes influencing coagulation and the risk of aneurysmal subarachnoid hemorrhage, and subsequent complications of secondary cerebral ischemia and rebleeding. Acta Neurochir. 2010;152(2):257–62.PubMedCrossRef

39.

Ariens RA, Lai TS, Weisel JW, Greenberg CS, Grant PJ. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood. 2002;100:743–54.PubMedCrossRef

40.

Qureshi SA, Bashir MU, Yaqinuddin A. Utility of DNA methylation markers for diagnosing cancer. Int J Surg. 2010;8(3):194–8.PubMedCrossRef

41.

Jin B, Li Y, Robertson KD. DNA methylation: superior or subordinate in the epigenetic hierarchy? Genes Cancer. 2011;2:607–17.PubMedPubMedCentralCrossRef

42.

Woodson K, Mason J, Choi SW, Hartman T, Tangrea J, Virtamo J, Taylor PR, Albanes D. Hypomethylation of p53 in peripheral blood DNA is associated with the development of lung cancer. Cancer Epidemiol Prev Biomarkers. 2001;10(1):69–74.

43.

Li L, Choi JY, Lee KM, Sung H, Park SK, Oze I, Pan KF, You WC, Chen YX, Fang JY, Matsuo K. DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology. J Epidemiol. 2012;22(5):384–94.PubMedPubMedCentralCrossRef

44.

Ma Y, Smith CE, Lai CQ, Irvin MR, Parnell LD, Lee YC, Pham L, Aslibekyan S, Claas SA, Tsai MY, Borecki IB. Genetic variants modify the effect of age on APOE methylation in the G enetics of L ipid L owering D rugs and D iet N etwork study. Aging Cell. 2015;14(1):49–59.PubMedCrossRef

Titel: Prognostic significance of factor XIIIA promoter methylation status in aneurysmal subarachnoid haemorrhage (aSAH)
verfasst von: S. Arati
G. K. Chetan
M. K. Sibin
Dhananjaya I. Bhat
Vikas Vazhayil
K. V. L. Narasingarao
Publikationsdatum: 01.12.2019
Verlag: BioMed Central
Erschienen in: BMC Cardiovascular Disorders / Ausgabe 1/2019
Elektronische ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-019-1146-8

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Prognostic significance of factor XIIIA promoter methylation status in aneurysmal subarachnoid haemorrhage (aSAH)